These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8665999)

  • 41. Comparison of adinazolam pharmacokinetics and effects in healthy and cirrhotic subjects.
    Kroboth PD; Maxwell RA; Fleishaker JC; Van Thiel DH; Smith RB
    J Clin Pharmacol; 1991 Jun; 31(6):580-6. PubMed ID: 1880225
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
    Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
    Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
    Khan AY; Preskorn SH; Horst WD
    J Pak Med Assoc; 2007 May; 57(5):230-5. PubMed ID: 17571477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
    Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
    Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment.
    Moton A; Krishna G; Ma L; O'Mara E; Prasad P; McLeod J; Preston RA
    Curr Med Res Opin; 2010 Jan; 26(1):1-7. PubMed ID: 19886860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.
    Nakada N; Kawamura A; Kamimura H; Sato K; Kazuki Y; Kakuni M; Ohbuchi M; Kato K; Tateno C; Oshimura M; Usui T
    Biopharm Drug Dispos; 2016 Jan; 37(1):3-14. PubMed ID: 26352195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment.
    Walsh AE; Cowen PJ
    J Clin Psychopharmacol; 1994 Aug; 14(4):268-73. PubMed ID: 7962683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
    Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
    Lam YW; Alfaro CL; Ereshefsky L; Miller M
    J Clin Pharmacol; 2003 Nov; 43(11):1274-82. PubMed ID: 14551182
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers.
    Robbins DK; Hutcheson SJ; Miller TD; Green VI; Bhargava VO; Weir SJ
    Biopharm Drug Dispos; 1997 May; 18(4):325-34. PubMed ID: 9158880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients.
    Ansseau M; Darimont P; Lecoq A; De Nayer A; Evrard JL; Krémer P; Devoitille JM; Dierick M; Mertens C; Mesotten F
    Psychopharmacology (Berl); 1994 Jun; 115(1-2):254-60. PubMed ID: 7862904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
    Namour F; Fagard L; Van der Aa A; Harrison P; Xin Y; Tasset C
    Br J Clin Pharmacol; 2018 Dec; 84(12):2779-2789. PubMed ID: 30088677
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
    Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of rizatriptan in healthy elderly subjects.
    Musson DG; Birk KL; Panebianco DL; Gagliano KD; Rogers JD; Goldberg MR
    Int J Clin Pharmacol Ther; 2001 Oct; 39(10):447-52. PubMed ID: 11680669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men.
    Salazar DE; Marathe PH; Fulmor IE; Lee JS; Raymond RH; Uderman HD
    J Clin Pharmacol; 1995 Nov; 35(11):1109-18. PubMed ID: 8626885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
    Abernethy DR; Barbey JT; Franc J; Brown KS; Feirrera I; Ford N; Salazar DE
    Clin Pharmacol Ther; 2001 Mar; 69(3):96-103. PubMed ID: 11240972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
    Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
    J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.